CCN-2 is up-regulated by and mediates effects of matrix bound advanced glycated end-products in human renal mesangial cells

Journal of Cell Communication and Signaling

Volumn 5, Issue 3, 2011, Pages 193-200

  Wang, Xiaoyu ^a   McLennan, Susan V ^a,b   Twigg, Stephen M ^a,b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Advanced glycation; CCN 2; CTGF; Diabetic nephropathy; Matrix

Indexed keywords

ADVANCED GLYCATION END PRODUCT; CONNECTIVE TISSUE GROWTH FACTOR; FIBRONECTIN; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CARBOHYDRATE SYNTHESIS; CELL EXPANSION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; GENE CONTROL; HUMAN; HUMAN CELL; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

EID: 80054966317     PISSN: 18739601     EISSN: 1873961X     Source Type: Journal    
DOI: 10.1007/s12079-011-0137-z     Document Type: Article

References (46)

1. Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, Striker G, Riser BL, LaPage J, Nast CC (2001) Glomerular mRNAs inhuman type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy. Kidney Int 60:2330-6 (Pubitemid 33070476)
2. Adler SG, Kang SW, Feld S, Cha DR, Barba L, Striker L, Striker G, Riser BL, LaPage J, Nast CC (2002) Can glomerular mRNAs in human type 1 diabetes be used to predict transition from normoalbuminuria to microalbuminuria? Am J Kidney Dis 40:184-8 (Pubitemid 34701227)
3. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, Neff TB, Urquilla PR, Sewell KL (2010) Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 5:1420-8
4. Beisswenger PJ, Makita Z, Curphey TJ, Moore LL, Jean S, Brinck-Johnsen T, Bucala R, Vlassara H (1995) Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes. Diabetes 44:824-829
5. Berlanga J, Cibrian D, Guillen I, Freyre F, Alba JS, Lopez-Saura P, Merino N, Aldama A, Quintela AM, Triana ME, Montequin JF, Ajamieh H, Urquiza D, Ahmed N, Thornalley PJ (2005) Methylglyoxal administration induces diabetes-like microvascular changes and perturbs the healing process of cutaneous wounds. Clin Sci (Lond) 109:83-95 (Pubitemid 40943037)
6. Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP (1998) AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 37:586-600 (Pubitemid 28231153)
7. Brooks BA, Franjic B, Ban CR, Swaraj K, Yue DK, Celermajer DS, Twigg SM (2008) Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 10:739-46
8. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P (2006) Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 17:2484-94 (Pubitemid 44300964)
9. Candido R, Forbes JM, Thomas MC, Thallas V, Dean RG, Burns WC, Tikellis C, Ritchie RH, Twigg SM, Cooper ME, Burrell LM (2003) A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res 92:785-92 (Pubitemid 36457644)
10. Chiarelli F, de Martino M, Mezzetti A, Catino M, Morgese G, Cuccurullo F, Verrotti A (1999) Advanced glycation end products in children and adolescents with diabetes: relation to glycemic control and early microvascular complications. J Pediatr Endocrinol Metab 134:486-491 (Pubitemid 30180632)
11. Chung AC, Zhang H, Kong YZ, Tan JJ, Huang XR, Kopp JB, Lan HY (2009) Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. J Am Soc Nephrol 21:249-60
12. Cooper ME (1998) Pathogenesis, prevention, and treatment of diabetic nephropathy. Lancet 352:213-9 (Pubitemid 28327814)
13. Gauer S, Segitz V, Goppelt-Struebe M (2007) Aldosterone induces CTGF in mesangial cells by activation of the glucocorticoid receptor. Nephrol Dial Transplant 22:3154-9 (Pubitemid 350202564)
14. Guha M, Xu ZG, Tung D, Lanting L, Natarajan R (2007) Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 21:3355-68 (Pubitemid 47565554)
15. King GL, Wakasaki H (1999) Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care 22:C31-C37 (Pubitemid 29164915)
16. Krishnamurti U, Rondeau E, Sraer JD, Michael AF, Tsilibary EC (1997) Alterations in human glomerular epithelial cells interacting with nonenzymatically glycosylated matrix. J Biol Chem 272:27966-70 (Pubitemid 27473602)
17. Lee CI, Guh JY, Chen HC, Lin KH, Yang YL, Hung WC, Lai YH, Chuang LY (2004) Leptin and connective tissue growth factor in advanced glycation end-product-induced effects in NRK-49F cells. J Cell Biochem 93:940-50
18. Lee CI, Guh JY, Chen HC, Hung WC, Yang YL, Chuang LY (2005) Advanced glycation end-product-induced mitogenesis and collagen production are dependent on angiotensin II and connective tissue growth factor in NRK-49F cells. J Cell Biochem 95:281-92
19. Lehmann R, Schleicher ED (2000) Molecular mechanism of diabetic nephropathy. Clin Chim Acta 297:135-44 (Pubitemid 30332284)
20. Liu N, Shimizu S, Ito-Ihara T, Takagi K, Kita T, Ono T (2007) Angiotensin II receptor blockade ameliorates mesangioproliferative glomerulonephritis in rats through suppression of CTGF and PAI-1, independently of the coagulation system. Nephron Exp Nephrol 105:e65-74 (Pubitemid 46438565)
21. Mason RM, Wahab NA (2003) Extracellular matrix metabolism in diabetic nephropathy. J Am Soc Nephrol 14:1358-73 (Pubitemid 36519197)
22. McLennan SV, Fisher EJ, Yue DK, Turtle JR (1994) High glucose concentration causes a decrease in mesangium degradation: a factor in the pathogenesis of diabetic nephropathy. Diabetes 43:1041-1045 (Pubitemid 24230710)
23. McLennan SV, Martell SK, Yue DK (2002) Effects of mesangium glycation on matrix metalloproteinase activities: possible role in diabetic nephropathy. Diabetes 51:2612-2618 (Pubitemid 34827414)
24. McLennan SV, Wang XY, Moreno V, Yue DK, Twigg SM (2004) Connective tissue growth factor mediates high glucose effects on matrix degradation through tissue inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy. Endocrinology 145:5646-55 (Pubitemid 39564606)
25. McLennan SV, Kelly DJ, Schache M, Waltham M, Dy V, Langham RG, Yue DK, Gilbert RE (2007) Advanced glycation end products decrease mesangial cell MMP-7: a role in matrix accumulation in diabetic nephropathy? Kidney Int 72:481-8 (Pubitemid 47237612)
26. Murphy M, Godson C, Cannon S, Kato S, Mackenzie HS, Martin F, Brady HR (1999) Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 274:5830-4 (Pubitemid 29109239)
27. Nakamura T, Fukui M, Ebihara I, Osada S, Tomino Y, Koide H (1994) Abnormal gene expression of matrix metalloproteinases and their inhibitors in glomeruli from diabetic rats. Renal Physiol Biochem 17:316-325 (Pubitemid 24329524)
28. Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, Orchard TJ (2009) Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 169:1307-16
29. Park SK, Kim J, Seomun Y, Choi J, Kim DH, Han IO, Lee EH, Chung SK, Joo CK (2001) Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 284:966-71 (Pubitemid 32924742)
30. Riser BL, Denichilo M, Cortes P, Baker C, Grondin JM, Yee J, Narins RG (2000) Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis. J Am Soc Nephrol 11:25-38 (Pubitemid 30020423)
31. Schleicher E, Nerlich A (1996) The role of hyperglycemia in the development of diabetic complications. Horm Metab Res 28:367-73 (Pubitemid 26290636)
32. Schmidt AM, Hori O, Brett J, Yan SD, Wautier JL, Stern D (1994) Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. Arterioscler Thromb Vasc Biol 14:1521-1528
33. Shi-Wen X, Renzoni EA, Kennedy L, Howat S, Chen Y, Pearson JD, Bou-Gharios G, Dashwood MR, du Bois RM, Black CM, Denton CP, Abraham DJ, Leask A (2007) Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biol 26:625-32 (Pubitemid 350186096)
34. Thomson SE, McLennan SV, Kirwan PD, Heffernan SJ, Hennessy A, Yue DK, Twigg SM (2008) Renal connective tissue growth factor correlates with glomerular basement membrane thickness and prospective albuminuria in a non-human primate model of diabetes: possible predictive marker for incipient diabetic nephropathy. J Diabetes Its Complicat 22:284-94 (Pubitemid 351885491)
35. Thornalley PJ (1998) Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol 44:1013-1023
36. Twigg SM (2011) Mastering a mediator: blockade of CCN-2 shows early promise in human diabetic kidney disease. J Cell Commun Signal 4:189-96
37. Twigg SM, Chen MM, Joly AH, Chakrapani SD, Tsubaki J, Kim HS, Oh Y, Rosenfeld RG (2001) Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: a potential mechanism for expansion of extracellular matrix in diabetes mellitus. Endocrinology 142:1760-9 (Pubitemid 32405931)
38. Twigg SM, Cao Z, McLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME (2002a) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143:4907-15 (Pubitemid 35397630)
39. Twigg SM, Joly AH, Chen MM, Tsubaki J, Kim HS, Hwa V, Oh Y, Rosenfeld RG (2002b) Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143:1260-9 (Pubitemid 34274355)
40. Vlassara H (1992) Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues. Diabetes 41:52-56
41. Vlassara H, Brownlee M, Cerami A (1986) Nonenzymatic glycosylation: role in the pathogenesis of diabetic complications. Clin Chem 32:B37-B41
42. Wahab NA, Weston BS, Mason RM (2005) Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 307:305-14 (Pubitemid 40803489)
43. Wang JF, Olson ME, Ball DK, Brigstock DR, Hart DA (2003) Recombinant connective tissue growth factor modulates porcine skin fibroblast gene expression. Wound Repair Regen 11:220-9 (Pubitemid 36648881)
44. Wang X, McLennan SV, Allen TJ, Tsoutsman T, Semsarian C, Twigg SM (2009) Adverse effects of high glucose and free fatty acid on cardiomyocytes are mediated by connective tissue growth factor. Am J Physiol Cell Physiol 297:C1490-500
45. Zhang C, Zhu Z, Liu J, Yang X, Fu L, Deng A (2007) Role of connective tissue growth factor in extracellular matrix degradation in renal tubular epithelial cells. J Huazhong Univ Sci Technolog Med Sci 27:44-7
46. Ziyadeh FN (1993) The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 22:736-44 (Pubitemid 23330946)